Most people meet this term in a pharmacy aisle rather than in a journal, which is part of the problem. On a shelf it looks like a brand. It is not one.
What AREDS2 stands for
Age-Related Eye Disease Study 2. The 2 is there because there was a first one, AREDS, published in 2001, and the second study was built to answer the questions the first one left open.
Both were run by the National Eye Institute, which is part of the US National Institutes of Health. That matters for one practical reason: the results are public, the formulation is public, and no company owns either. When a bottle says AREDS2, it is naming somebody else's research.
Two different things share the name
This causes more confusion than any other part of the topic, so it is worth being blunt about it.
- The study. A trial of just over 4,000 people, all of whom already had a meaningful degree of age-related macular degeneration, followed for five years and then revisited a decade later.
- The formulation. The specific combination of six nutrients, at specific amounts, that the study arrived at. This is what people mean when they say they take AREDS2.
A product can reproduce the second while having no connection at all to the first, which is normal and fine. A product can also print the letters while reproducing only part of the formulation, which is where buyers get caught. We go through what the name on a box does and does not guarantee separately.
What the trials actually found
AREDS, 2001: the original result
The first study tested high-dose vitamin C, vitamin E, beta-carotene, and zinc against placebo. In participants who already had intermediate AMD, or advanced AMD in one eye, the combination was associated with roughly a 25% reduction in the risk of progressing to advanced disease over five years.
That number is the reason any of this exists. It is also routinely misquoted. It is not a 25% improvement in vision, and it is not a 25% chance of avoiding AMD. It is a relative reduction in the risk of getting worse, in people who were already some way down that road.
AREDS2, 2013: what changed
The second study asked three questions. Would adding lutein and zeaxanthin help? Would adding omega-3 fatty acids help? Could the zinc dose come down, and could beta-carotene come out?
- Omega-3 fatty acids added nothing measurable. This is worth remembering when a product charges extra for fish oil.
- Lutein and zeaxanthin turned out to be a suitable replacement for beta-carotene, which mattered because beta-carotene had a safety problem in smokers.
- Zinc at 25 mg performed the same as zinc at 80 mg. Products still market the higher number as a feature. The trial found no difference between them.
The 10-year follow-up, 2022
A decade after the trial ended, the researchers went back to the participants. Two findings came out of it. The lutein and zeaxanthin version continued to be associated with a lower risk of progression to late AMD. And the beta-carotene safety signal held: among people randomised to beta-carotene, the odds of having lung cancer were nearly double, concentrated in former smokers, while the lutein and zeaxanthin group showed no comparable increase.
What is in the formulation
Six ingredients, at these amounts, taken daily. Most products split the daily amount across two capsules rather than one.
| Nutrient | Amount | What it is doing |
|---|---|---|
| Vitamin C | 500 mg | Antioxidant. Part of the original 2001 combination. |
| Vitamin E | 400 IU (180 mg) | Antioxidant. Both numbers describe the same dose in different units. |
| Lutein | 10 mg | Pigment the macula concentrates. Replaced beta-carotene. |
| Zeaxanthin | 2 mg | The second macular pigment, tested alongside lutein. |
| Zinc | 80 mg or 25 mg | Both amounts were tested. No difference was found between them. |
| Copper | 2 mg | Present to offset the zinc, which interferes with copper absorption. |
Amounts as published by the National Eye Institute and reproduced on the manufacturer's professional materials. If a panel prints vitamin E as 180 mg rather than 400 IU, that is the newer labelling unit for the same dose, not a smaller product.
The copper is the ingredient people skip, and it is the one worth caring about. Sustained high-dose zinc drives copper down over time, and the trial included copper specifically to stop that happening. A product listing zinc with no copper has dropped a safety component, not an optional extra. What each ingredient is doing goes through the reasoning one by one.
What AREDS2 does, and what it does not do
The honest description is narrow, and the narrowness is the point.
Reading the evidence as it stands
What the trials found
- A lower risk of progressing to advanced AMD.
- In people with intermediate AMD, or advanced AMD in one eye.
- Over roughly five years of daily use, sustained at ten.
- From the full six-nutrient combination, not from parts of it.
What they did not find
- Any benefit in eyes with no AMD or very early AMD.
- Any improvement in eyesight or sharpness.
- Any effect on cataracts, glaucoma, or dry eye.
- Any reason to expect prevention in a healthy retina.
So the answer to whether AREDS2 works depends entirely on who is asking. For the group the trials studied, it is one of the better-evidenced interventions in eye health. For everyone else, the trials are not ambiguous and they are not encouraging. They found nothing.
Who the evidence covers
Intermediate AMD in one or both eyes, or advanced AMD in one eye. That is the group, and it is a clinical definition rather than a description of symptoms.
This is the part that catches people out. Intermediate AMD is usually symptomless. It is defined by what an examiner sees at the back of the eye, mainly the size and number of drusen and any pigment changes, so you cannot work it out from how your vision feels. It takes a dilated exam and a direct question about what stage you are at.
We cover who the evidence supports and who it does not in more detail, including what to ask at an appointment. There is also a one-page version you can print and take with you.
The dosage, and why it looks so high
Most products deliver the full amounts across two capsules a day, commonly one in the morning and one in the evening, taken with food. The carotenoids and vitamin E are fat-soluble, so food containing some fat genuinely helps, which is one of the few absorption claims in this category with anything behind it.
The amounts sit well above anything you would get from a diet, and that is deliberate. This was designed as a pharmacological intervention that happens to be assembled from nutrients. Which is also why improvising your own version from separate bottles is a poor idea, and why stacking it on top of a multivitamin without telling anyone is worth avoiding. Zinc at these levels interacts with things.
Why the name on a shelf means less than you would expect
Because AREDS2 is a study name rather than a trademark, nobody audits its use. There is no body that checks whether a product carrying those letters reproduces the formulation, and no penalty for stretching them.
In practice this produces products that are exact reproductions, products carrying half the amounts, products that drop one of the six, and at least one product line using a number the research never assigned. Sorting them takes one document, and it is not the front of the box. It is the supplement facts panel. We compared what the labels of the main products actually state, and you can run any panel through our label checker.